March 2021 Nasdaq: QLGN Forward-Looking Statements This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including whether preclinical or clinical development of our drugs or therapeutic devices wil ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (I.R.S. Employer ...

Financial Data and Key Metrics Changes - Total revenue for the current quarter was approximately $900,000, down $600,000 from the same period in 2019, primarily due to the COVID-19 pandemic affecting non-essential patient visits [32] - Loss from operations increased to $2.6 million from a $500,000 loss in the prior year period, mainly due to higher G&A expenses and reduced gross profit from declining product sales [37] - Net loss for the first quarter of fiscal 2021 was $18.6 million, compared to a net loss of $600,000 for the same period last year, largely due to a non-cash charge of $16.2 million related to a derivative liability [38] Business Line Data and Key Metrics Changes - The diagnostics business faced challenges with sales negatively impacted by the pandemic, resulting in fewer FastPack tests performed [32] - R&D expenses totaled approximately $600,000, with higher costs related to sponsored therapeutics research at the University of Louisville [34][35] - The company is shifting its overall R&D spending towards therapeutics, indicating a strategic focus on drug development over diagnostics [36][29] Market Data and Key Metrics Changes - The diagnostics market is highly competitive, facing headwinds from declining reimbursements and the pandemic's impact on patient visits [39] - The company is actively working to increase production capacity for its COVID-19 antibody test, which is expected to be a significant market opportunity [24][27] Company Strategy and Development Direction - The company has expanded its therapeutics pipeline by signing exclusive licensing agreements for drug candidates targeting cancer and viral diseases [6][11] - The focus is on developing drug candidates like AS1411 and ALAN, which are seen as having significant market potential [18][29] - The company aims to establish strategic partnerships to advance clinical development of its drug candidates [17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future of therapeutic drug development, despite acknowledging the challenges of the drug development process [18] - The company believes that progress towards the commercialization of drug candidates is a better measure of long-term value than diagnostics revenue [39] Other Important Information - The company raised $18 million in capital through registered direct offerings, providing a stronger balance sheet to support operations [30] - The FastPack PRO System is expected to generate revenue in the current quarter, with gradual increases anticipated as manufacturing ramps up [42] Q&A Session Summary Question: When do you expect to start booking revenues on the FastPack PRO? - Management expects to recognize revenue from the sale of COVID-19 antibody tests in the current quarter, with gradual increases in subsequent quarters as manufacturing ramps up [42] Question: What is the timeline for IND filings and human trials for AS1411 and ALAN? - The IND for AS1411 is aimed for October, with human trials expected to begin early in 2021. For ALAN, the IND filing is anticipated in the second quarter of 2021 [44] Question: Can you provide details on the COVID clinical trial? - The clinical trial will involve several arms, including AS1411 alone and AS1411 plus standard-of-care, with a total of about 500 patients across 20 sites [51] Question: What is the expected cash burn rate and runway with the current cash position? - The company expects a cash burn of about $2 million per quarter, providing approximately two years of runway with the current cash position of $16 million [48]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (I.R.S. Employer Identification No.) (State or other jurisdiction of incorporation) 2042 Corte Del Nogal, Carlsbad, California 92011 (Address of principal executive offices) (Zip Code) (760) 918-9165 (Registrant's telephone number, including area code) For the quarterly period ended June 30, 2020 Or [ ] TRANSITION REPORT PURSUANT TO SEC ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 001-37428 RITTER PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37428 RITTER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 26-3474527 (State or other jurisdiction of incorporation or orga ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 001-37428 RITTER PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) (State or ot ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 001-37428 RITTER PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) (State or other j ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 001-37428 RITTER PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) (State or other ...

For the fiscal year ended December 31, 2018 or UNITED STATES SECURITIES AND EXCHANGE COMMISSION [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 Commission File Number 001-37428 RITTER PHARMACEUTICALS, INC. FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Title of Each Class Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share NASDAQ Capital Market Sec ...